Summary
Advanced colorectal cancer was the first human malignancy in which inhibition of angiogenesis by targeting vascular endothelial growth factor (VEGF) led to a significant survival benefit in a randomized phase III trial. Since then, bevacizumab, a monoclonal antibody against VEGF, has become a standard component of palliative medical therapy in this disease. Various other angiogenesis inhibitors, in particular, inhibitors of VEGF-receptor kinases are currently undergoing testing in clinical trials, either as single agents or in combination with chemotherapy or other targeted agents. In addition, clinical research is currently focusing on the use of anti-VEGF-therapy in the adjuvant and neoadjuvant setting, as well as its usefulness as maintenance therapy to stabilize responses achieved with conventional cytotoxic chemotherapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of Fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23:9441–2, 2005.
Falcone A, Masi G, Brunetti I, et al. The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (mcolorectal cancer): results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.). J Clin Oncol (Meeting Abstracts) 24:3513, 2006.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–42, 2004.
Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol (Meeting Abstracts) 23:2, 2005.
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–45, 2004.
Peeters M, Van Cutsem E, Siena S, et al. A Phase 3, Multicenter, Randomized Controlled Trial (RCT) of Panitumumab Plus Best Supportive Care (BSC) vs BSC Alone in Patients (pts) with Metastatic Colorectal Cancer (Mcolorectal Cancer). American Association for Cancer Research, Washington, DC, 2006, Abstract CP-1.
Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–5, 2003.
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–14, 2000.
Mass RD, Sarkar S, Holden SN, et al: Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mcolorectal cancer). J Clin Oncol (Meeting Abstracts) 23:3514, 2005.
Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502–8,2005.
Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697–705, 2005.
Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706–12, 2005.
Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30, 2004.
Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mcolorectal cancer): final analysis of the TREE-Study. J Clin Oncol (Meeting Abstracts) 24:3510, 2006.
Cassidy J, Clarke S, Diaz Rubio E, et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (Mcolorectal cancer). Ann Oncol 17 (Suppl 9):LBA 3, 2006.
Fuchs C, Marshall J, Mitchell E, et al. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). J Clin Oncol (Meeting Abstracts) 24:3506, 2006.
Saltz LB, Lenz HJ, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol 23:abstract 3508, 2005.
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–40, 2004.
Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–7, 2004.
Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565–70, 2000.
Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–64, 2003.
Schleucher N, Trarbach T, Junker U, et al. Phase I/II study of PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol 22:3558, 2004.
Steward WP, Thomas A, Morgan B, et al. Expanded phase I/II study of PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol 22:3556, 2004.
Hecht J, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol 23:abstract LBA 3, 2005.
Koehne C, Bajetta E, Lin E, et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mcolorectal cancer) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J Clin Oncol (Meeting Abstracts) 24:3508, 2006.
Major P, Trarbach T, Lenz H, et al. A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mcolorectal cancer) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. J Clin Oncol (Meeting Abstracts) 24:3529, 2006.
Thomas AL, Morgan B, Horsfield MA, et al. Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer. J Clin Oncol 23:4162–71, 2005.
Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J 7(Suppl 3):S120–8, 2001.
Mendel DB, Schreck RE, West DC, et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 6:4848–58, 2000.
Anonymous. Pharmacia’s SU5416 not effective. Expert Rev Anticancer Ther 2:5, 2002.
H. Lenz, J. Marshall, L. Rosen, R. Belt, H. Hurwitz, S. Eckhardt, E. Bergsland, D. Haller, R. chao, L. Saltz. Phase II trail of SU11248 in patients with metastatic colorectal cancer (MCRC) after failure of standard chemotherapy 2006. Gastrointestinal cancers symposium, Abstract No. 241.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press
About this chapter
Cite this chapter
Grothey, A. (2008). Antiangiogenesis Agents in Colorectal Cancer. In: Teicher, B.A., Ellis, L.M. (eds) Antiangiogenic Agents in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-184-0_22
Download citation
DOI: https://doi.org/10.1007/978-1-59745-184-0_22
Publisher Name: Humana Press
Print ISBN: 978-1-58829-870-6
Online ISBN: 978-1-59745-184-0
eBook Packages: MedicineMedicine (R0)